Neuphoria Therapeutics Inc.

For the period ended Jun 30, 2026. Filed Sep 18, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2026 · Filed Sep 18, 2026

NEUP$2.76-0.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

	June 30,	June 30,
	2026	2025
Assets
Current assets
Cash and cash equivalents	$19,865,531	$14,210,745
Accounts receivable, non-trade	813,431	11,948
Restricted cash	-	77,945
Prepaid expenses	389,772	740,193
Total current assets	21,068,734	15,040,831
Property and equipment, net	-	2,771
Intangible assets, net	4,142,060	4,804,791
Operating lease right-of-use assets	-	102,612
Goodwill	3,498,222	8,638,609
Total assets	$28,709,016	$28,589,614
Liabilities and Shareholders’ Equity
Current liabilities
Accounts payable	$385,584	$1,154,369
Accrued expenses and other current liabilities	370,997	2,950,077
Operating lease liability	-	116,314
Total current liabilities	756,581	4,220,760
Contingent consideration	1,025,301	1,169,675
Deferred tax liability	355,940	495,113
Accompanying warrant liability	1,971,172	3,701,492
Total liabilities	4,108,994	9,587,040
Commitments and contingencies (Note 18)
Shareholders’ equity
Common stock, $0.00001 par value, 5,411,334 and 1,978,460 shares issued and outstanding at June 30, 2026 and 2025, respectively	54	19
Additional paid-in capital, net of subscription receivable	218,461,772	200,194,324
Accumulated other comprehensive loss, net of tax	(2,063,170)	(2,845,066)
Accumulated deficit	(191,798,634)	(178,346,703)
Total shareholders’ equity	24,600,022	19,002,574
Total liabilities and shareholders’ equity	$28,709,016	$28,589,614

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.